Dear Sir or Madam,
Dear Patients, Participants, Collaborators and Employees
WE INFORM and REMIND that from 14.04.2020 (until further notice), the DUTY to wear protective masks has been imposed on the entire CBK PI-House Center.
We kindly ask you to comply with the above message.
Thank you.
Centrum Badań Klinicznych PI-House sp. z o. o.
NIP: 9571059089 | EU VAT ID: PL9571059089
REGON: 221506777 | KRS: 0000394618
Share capital: PLN 60,000
Entry number in the Register of
Health Care Providers: 000000154510
Medi Medic Centrum Medyczne
Study title: Open-label long-term safety study of esketamine nasal spray dose extension in treatment-resistant depression
Therapeutic area: Treatment-resistant depressive disorder
Phase: III
Start Date: June 9, 2016
End date: December 31, 2022
Status: Not recruiting
Sponsor Name: Janssen Research & Development, LLC
Study title: Long-term, multicentre, randomized, double-blind, controlled, parallel group study of the safety and efficacy of Lemborekxant in people with insomnia disorders
Therapeutic area: Disorder of insomnia
Phase: III
Start Date: November 15, 2016
End date: January 8, 2019
Status: Not recruiting
Sponsor Name: Eisai Inc.
Study title: Adaptive, multicentre, prospective, randomized, double-blind, placebo-controlled phase IIb / III study of the safety and efficacy of NaBen® (DAAO inhibitor) as an additional treatment for schizophrenia in adults
Therapeutic area: schizophrenia
Phase: IIb / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx
Study title: Adaptive Phase II / III study, two-part, double-blind, randomized, placebo-controlled, dose-titled multicenter study of the safety and efficacy of NaBen® as add-on therapy with clozapine for the treatment of symptoms of refractory schizophrenia in adults
Therapeutic area: schizophrenia
Phase: II / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx
English (UK) 
Polski